Gene expression profiles (GEPs) of immuno-oncologic pathways as predictors of response to checkpoint inhibitors in advanced NSCLC
Authors:
- Pedro De MarchiPMPedro De Marchi
- Luciane Sussuchi da SilvaLSLuciane Sussuchi da Silva
- Rodrigo de Oliveira CavagnaRCRodrigo de Oliveira Cavagna
- Vinicius Duval da SilvaVSVinicius Duval da Silva
- Eduardo Ca da SilvaESEduardo Ca da Silva
- Vladmir C. Cordeiro de LimaVLVladmir C. Cordeiro de Lima
- Rui Manuel ReisRui Manuel Reis
Open Access
- 31 October 2023
- journal article
- research article
- Published by Elsevier in Translational Oncology
- Vol. 39, 101818
Abstract
No abstract availableKeywords
Funding Information
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Financiadora de Estudos e Projetos (02/2010)
- Hospital de Câncer de Barretos
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
This publication has 43 references indexed in Scilit:
- Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and MelanomaCancer Research, 2017
- Detection of ALK fusion transcripts in FFPE lung cancer samples by NanoString technologyBMC Pulmonary Medicine, 2017
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trialThe Lancet, 2017
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerNew England Journal of Medicine, 2016
- Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancerAnnals of Oncology, 2016
- Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2016
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialThe Lancet, 2016
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trialThe Lancet, 2016
- The 2015 World Health Organization Classification of Lung TumorsJournal of Thoracic Oncology, 2015
- An immune-active tumor microenvironment favors clinical response to ipilimumabCancer Immunology, Immunotherapy, 2011